Cell therapies for heart ailments involve transplanting over a billion heart cells to the patient’s heart. Many of these cells fail to engraft, however, compromising the benefits. One reason for the poor engraftment is that normally the heart cell population is a mixture of cells with different maturation. Researchers have now identified an ideal maturation stage that enhances engraftment and may reduce the number of cells required for therapy.
Under the direction of Sr Lecturer Yoshinori Yoshida, Dr Funakoshi took induced pluripotent stem (iPS) cells that were reprogrammed from skin cells and made them into heart cells...
Read More
Recent Comments